This is mainly an execution-and-expectations risk story, not a science-project story. The technology is real and demand exists, but the company must prove that the Renesas carve-out expands
socket share, not just revenue scale, while maintaining premium
gross margins and absorbing supply commitments. Concentrated distributors and customers can magnify normal inventory swings, and the stock still carries enough optimism that decent revenue growth alone may not protect the multiple if execution gets messy.